Wir sind mit live! Mehr erfahren

NeuroOne Medical Technologies

NMTC

Börsenwert 8,75 Mio. $

0,9614 USD

-0,0786

7,56 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

1,00

+0,04

4,01 %

1 Tag

-7,56 %

5 Tage

-12,6 %

1 Monat

-31,82 %

3 Monate

-59,43 %

6 Monate

-78,96 %

Seit Jahresbeginn

-81,19 %

1 Jahr

-81,44 %

5 Jahre

-94,57 %

10 Jahre

-97,79 %

Profil: NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

Mitarbeiter: 18

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 100 %

Negativ 0 %

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System.

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q3 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript

Zacks Investment Research

Best Momentum Stocks to Buy for January 6th

RIGL, CM and NMTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6th, 2026.

Best Momentum Stocks to Buy for January 6th

Zacks Investment Research

New Strong Buy Stocks for January 6th

ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.

New Strong Buy Stocks for January 6th

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt